| Formerly | ViroLogic Inc. |
|---|---|
| Type | Subsidiary |
| Nasdaq: MGRM | |
| Industry | Biotechnology |
| Headquarters | South San Francisco, California |
| Products | PhenoSense, PhenoSense GT, Trofile, GeneSeq, VeraTag, HERmark |
Number of employees | 379 (2008) |
| Parent | LabCorp |
| Website | www |
| Footnotes 1 | |
Monogram Biosciences, Inc. (formerly ViroLogic Inc.) is an international biotechnology laboratory located in South San Francisco, California, USA and is a subsidiary of LabCorp. Monogram develops and markets assays to help guide and improve the treatment of infectious diseases (including HIV and Hepatitis) and cancer.
Virologic was founded in 1996 by Daniel Capon, Ph.D., Martin Goldstein and Robert S. Capon. The company went public (NASDAQ: VLGC) in 2000.2
Monogram was acquired by Laboratory Corporation of America in June 2009.3
References
References
- "FORM 10-K".
- SEC. "Monogram Biosciences, Inc. 2000 Quarterly Report 10-Q". SEC.report. p. 10. Retrieved 2020-06-22.
- "LabCorp Successfully Completes Acquisition of Monogram Biosciences, Inc". Business Wire. Retrieved 28 May 2010.
External links
External links
- Official website
- Baseline HIV Type 1 Coreceptor Tropism Predicts Disease Progression [1]
- Four Studies Affirm Significance Of Monogram's Trofile(TM) HIV Co-Receptor Tropism Assay [2]
- Accuracy of Monogram's Trofile Assay in Determining Tropism and New Tropism Assays in Development [3]
- Trofile Bests SensiTrop as Most Reliable Tropism Test [4]
- Monogram Biosciences teams up with Pfizer for HIV treatment [5]
- Monogram Biosciences Launches New "Trofile" HIV Co-receptor Tropism Test to Select Patients Eligible to User CCR5 Antagonist Maraviroc (Selzentry) [6]